Multinational biopharmaceutical company UCB has agreed to invest £1 billion in UK research and development (R&D) over the next five years, the government has announced in its latest Life Sciences Sector Deal. In the deal, £75 million will be invested into the development of new AI driven diagnostic tests, £50 million will be invested in digital pathology programmes and £37.5 million will go into regional digital innovation hubs.

UCB’s investment will be focused on a new £150 to £200 million purpose-built research facility set to support 650 new jobs, as many as UCB currently employees in the UK and Ireland.

UCB’s new state-of-the-art facility will allow for better development of innovative treatments for patients, and will include an early manufacturing facility and a hub for UK commercial operations.

CEO of UCB Jean-Christophe Tellier said the new development would enable the company to further a number of active collaborations with UK universities, biotechs and medical research charities.